Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptides and methods for detecting peanut allergies

A technology of peanut peptides and peanuts, applied in chemical instruments and methods, allergic diseases, peptide sources, etc.

Pending Publication Date: 2021-01-26
过敏原有限责任公司 +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

IgE against Ara h 2 predicts clinical responsiveness to peanut (Lieberman et al., J. Allergy Clin. Immunol. Pract., 2013, 1, 75-82), but there are substantial clinical responses among individuals with similar Ara h 2 levels. Heterogeneity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptides and methods for detecting peanut allergies
  • Peptides and methods for detecting peanut allergies
  • Peptides and methods for detecting peanut allergies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1: Analysis of the LEAP cohort using epitope assays

[0122] As background, randomized controlled trials (RCTs) (eg, Learning Early About Peanut allergy (LEAP)) have previously been conducted to determine the best strategies for preventing peanut allergy in young children. The LEAP trial consisted of 640 children between the ages of 4 and 11 months who were identified as being at high risk for peanut allergy. The children were divided into two groups: avoidant and edible (snacks containing peanuts, >3 meals; 6 g peanut protein per week). The results of this trial showed that the proportion of children developing peanut allergy at 5 years of age was 4- to 6-fold higher in the avoidance group compared with the eating group, as measured by the oral food challenge (OFC). The results of the LEAP trial are published eg in Toit et al., N. Engl. J. Med., 2015, 372, 803-813. As a result, the trial led to changes in U.S. guidelines for peanut allergy prevention.

[012...

Embodiment 2

[0149] Example 2: Evaluation of an epitope classifier for predicting peanut allergy

[0150] To assess the diagnostic suitability of IgE and IgG4 epitope reactivity using this same (LEAP) cohort, patients whose final diagnosis was confirmed by OFC were selected to develop algorithms and identify classifiers for predicting allergy.

[0151] IgE / IgG4 epitope-specific binding was assessed over 5 years using samples from 341 children at high risk of peanut allergy recruited in the LEAP trial ( Figure 7 ). IgE epitope-specific antibodies were developed in patients in the avoidance group and were specific for patients with peanut allergy at 5 years of age mainly in two regions (see Figure 7 , green arrow, left). IgG4 epitope-specific antibodies were increased in all patients, suggesting that peanut exposure occurred through a non-oral route in peanut avoiders. In particular, peanut eaters produced IgG4 early (see Figure 7 , right panel), particularly in the region of interest...

Embodiment 3

[0165] Embodiment 3: test

[0166] Based on the robust data presented here, the binding patterns of IgE / IgG4 to peanut epitopes are expected to be informative and useful for characterizing the severity of allergic disease in patients, assessing patients longitudinally to guide initial and inter-study dosing, during the study Tracking or predicting adverse events (to improve safety), confirming patients' allergic status at clinical endpoints of treatment, and monitoring patients after treatment to determine if / when additional therapy is needed to maintain treatment responsiveness.

[0167] Subgroups of patient samples will be identified. At a minimum, samples will include Ar101-treated and placebo groups that include patients who: 1) remain in the study until the clinical endpoint; 2) continue to be monitored after the clinical endpoint to assess ongoing non-responsiveness; 3) due to 4) withdraw from the study without adverse reactions; 5) have available serum composition and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides peptide biomarkers, including methods and kits employing the same, for diagnosis of peanut allergy, and tolerance thereto, and for determining whether an allergic subject is likely to outgrow the allergy.

Description

technical field [0001] The present disclosure relates in part to peptide biomarkers, including methods and kits for using them, for diagnosing peanut allergy and for determining whether allergic subjects are likely to outgrow allergy. Background technique [0002] Food allergy is a common problem in adults and children, and symptoms can range from mild oral itching to potentially life-threatening anaphylactic shock. Food allergy is currently diagnosed by skin prick testing or oral challenge and measuring serum levels of specific IgE and, in some cases, other serum antibodies such as IgG4. Although these tests indicate the likelihood of a clinical response, they do not distinguish between different phenotypes of food allergy or provide prognostic information. Current allergy testing also poses a degree of risk to patients. Current IgE tests have a weak relationship with a patient's actual clinical sensitivity, which is usually defined as a combination of the severity of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/02G01N33/53G01N33/543G01N33/564G01N33/68
CPCA61P37/08G01N33/6854G01N33/6893G01N2800/24A61K39/35C07K14/415
Inventor R·C·盖茨P·科尔尼H·A·桑普森M·苏亚雷斯-法里纳斯
Owner 过敏原有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com